- From: Kei Cheung <kei.cheung@yale.edu>
- Date: Wed, 28 May 2008 15:39:52 -0400
- To: Elizabeth Wu <ewu@alzforum.org>
- Cc: kc28@email.med.yale.edu, 'Tim Clark' <twclark@nmr.mgh.harvard.edu>, "'M. Scott Marshall'" <marshall@science.uva.nl>, public-semweb-lifesci@w3.org
Hi Elizabeth et al., I just found the following document. http://www.aan.com/professionals/practice/pdfs/dementia_guideline.pdf which summarizes several guidelines with respect to detection, diagnosis, treatment, and management of dementia (e.g., alzheimer). A colleague of mine referred me to the following website (American Academy of Neurology): http://www.aan.com which has a full version of these guidelines. I wonder if this would be of help to classify AD patients for inclusion/exclusion in a clinical trial or to analyze patient data retropectively. I also wonder if this would be of interest to folks with clinical ontology background. Thanks, -Kei Elizabeth Wu wrote: > Hi Kei, > > There is an entry in the Drugs in Clinical Trials section of Alzforum on > Huperzine A http://www.alzforum.org/drg/drc/detail.asp?id=53. The drug is > currently in Phase IV clinical trial in China and phase II in the US. Its > proposed actions are linked to many of the AD hypotheses, and I would think > that if there are sources on research on herbs that could provide more > insight, it would be of interest to the community. > > Best, > > Elizabeth > > Elizabeth Wu > Alzheimer Research Forum > > > -----Original Message----- > From: public-semweb-lifesci-request@w3.org > [mailto:public-semweb-lifesci-request@w3.org] On Behalf Of > kc28@email.med.yale.edu > Sent: Sunday, May 25, 2008 10:41 PM > To: Tim Clark > Cc: M. Scott Marshall; public-semweb-lifesci@w3.org > Subject: Re: KB note > > > Hi Tim et al., > > I think it would be great if more details about SWAN can be added. The HCLS > ecosystem consists of scientists, patients, doctors, government agencies, > publishers, etc. Creating/maintaining a balance in this digital age across > national boundaries is challenging/interesting. > > Speaking of national boundaries, I wonder if alternative medicine (e.g., > herbal > medicine) would also be of interest to this community. For example, > Huperzine > is a drug derived from the herb Huperzia serrata. I also wonder if there are > hypotheses regarding the study of herbs in the possible treatment of > neurological diseases. > > Thanks, > > -Kei > > > Quoting Tim Clark <twclark@nmr.mgh.harvard.edu>: > > >> Hi Scott, >> >> Your KB note lists no details about SWAN - we would like to see them >> included. I'll forward something to you in a separate email later >> today. >> >> Best >> >> Tim >> >> Tim Clark >> Director of Informatics, MassGeneral Institute for Neurodegenerative >> Disease >> Instructor in Neurology, Harvard Medical School >> 617-947-7098 (mobile) >> >> On May 23, 2008, at 6:59 PM, M. Scott Marshall wrote: >> >> >>> The KB note is ready for a last round of feedback and corrections. >>> We have until the end of the month to publish so please be speedy >>> with feedback. You can view the Editor's working draft at: >>> >> http://www.w3.org/2001/sw/hcls/notes/kb/ >> >>> Thanks, >>> Scott >>> >>> -- >>> M. Scott Marshall >>> tel. +31 (0) 20 525 7522 >>> http://staff.science.uva.nl/~marshall >>> http://adaptivedisclosure.org >>> >>> >>> >>> >>> >> >> >> > > > > >
Received on Wednesday, 28 May 2008 19:40:39 UTC